Nina Stojcheva
Molecular Partners (Switzerland)(CH)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Peptidase Inhibition and Analysis, MicroRNA in disease regulation, Hepatocellular Carcinoma Treatment and Prognosis, Lung Cancer Diagnosis and Treatment
Most-Cited Works
- → MicroRNA-138 promotes acquired alkylator resistance in glioblastoma by targeting the Bcl-2-interacting mediator BIM(2016)63 cited
- → MiR‐16‐5p is frequently down‐regulated in astrocytic gliomas and modulates glioma cell proliferation, apoptosis and response to cytotoxic therapy(2018)50 cited
- → Transcriptional control of O6‐methylguanine DNA methyltransferase expression and temozolomide resistance in glioblastoma(2018)34 cited
- → Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08)(2019)11 cited
- → Effect of MP0317, a FAP x CD40 DARPin, on safety profile and tumor-localized CD40 activation in a phase 1 study in patients with advanced solid tumors.(2024)5 cited
- → Phase I study of MP0317, a FAP-dependent DARPin, for tumor-localized CD40 activation in patients with advanced solid tumors.(2023)5 cited
- → The Designed Ankyrin Repeat Protein Antiviral Ensovibep for Nonhospitalized Patients With Coronavirus Disease 2019: Results From EMPATHY, a Randomized, Placebo-Controlled Phase 2 Study(2024)3 cited
- → 612 Comprehensive biomarker analyses from a phase 1 study reveals marked tumor microenvironment modulation in patients with advanced solid tumors treated with MP0317, a FAP-localized CD40 agonistic DARPin(2024)1 cited
- → 1475 A phase 1 study to characterize the safety and tolerability of MP0317, a tumor targeting FAP dependent CD40 agonist DARPin, in patients with relapsed/refractory solid tumors(2022)1 cited
- → SAKK 57/16 nab-paclitaxel and gemcitabine in soft tissue sarcoma (NAPAGE): Results from the phase I part of a phase I/II trial(2019)